Latest Ratios: P/E Ratio -8.0x · EV/EBITDA N/A · ROE -58.9%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $1.6B | $774M | $838M | — | — | — |
| Enterprise Value | $1.6B | $728M | $764M | — | — | — |
| P/E Ratio → | -7.96 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 4.30 | 2.52 | 3.25 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -58.9% | -58.9% | -39.4% | -42.6% | -34.2% | -125.2% |
| ROA | -54.7% | -54.7% | -36.7% | -40.1% | -32.7% | -119.9% |
| ROIC | -59.8% | -59.8% | -76.6% | -898.4% | -364.9% | — |
| ROCE | -62.9% | -62.9% | -46.1% | -45.8% | -34.2% | -21.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.15 | -0.29 | -0.99 | -0.94 | -0.90 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($46M) exceeds total debt ($14000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 12.83 | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
| Quick Ratio | 12.83 | 12.83 | 13.14 | 13.76 | 21.84 | 23.63 |
| Cash Ratio | 12.06 | 12.06 | 12.67 | 12.94 | 19.54 | 20.51 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $38M | $31M | $32M | $33M | $1M |
Binary clinical trial failure
Based on reported figures, ArriVent trades at a price-to-book ratio of 4.26, which appears to reflect a significant discount relative to peers like Nuvalent and Erasca, suggesting the market is heavily discounting the firm's future potential until definitive Phase 3 clinical data is successfully delivered.
The current valuation multiple is largely a function of the company's remaining cash balance rather than any underlying earnings power, which is typical for pre-revenue biotech. Investors should interpret this P/B ratio as a proxy for the market's confidence in the FURVENT trial, as any deviation from expected clinical outcomes would likely lead to a rapid compression of this multiple.
As reported in financial statements, ArriVent's ROIC has remained consistently negative, reaching -13.2% in 2026Q1, which underscores the structural reality that the company is currently consuming capital to build future value rather than generating returns on its existing invested capital base.
The persistent negative ROIC is an expected outcome for a clinical-stage entity, but the trend warrants monitoring as the company approaches potential commercialization. The lack of positive returns suggests that the firm's primary value creation mechanism is currently tied to clinical de-risking rather than operational efficiency or capital compounding.
According to recent SEC filings, ArriVent's current ratio has fluctuated significantly, settling at 13.95 in 2026Q1, which indicates a high level of short-term liquidity but masks the underlying reality that this cash is being rapidly depleted to fund ongoing, non-discretionary clinical trial expenses.
While the current ratio appears robust compared to industrial peers, it is a misleading metric for a biotech firm that lacks recurring revenue to replenish its working capital. The company's liquidity position is essentially a countdown clock, and investors should focus on the burn rate relative to the remaining cash balance rather than traditional liquidity ratios.
Financial analysts frequently misapply traditional profitability metrics like net margin to ArriVent, which obscures the firm's true economic health by failing to account for the fact that R&D spending is a strategic investment in future assets rather than a standard operating expense.
Using net margin to evaluate this business model is fundamentally flawed because it treats essential clinical development costs as a sign of operational failure. A more appropriate analytical framework would involve assessing the risk-adjusted net present value of the lead asset, furmonertinib, rather than focusing on the accounting losses generated during the development phase.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AVBP stock.
ArriVent BioPharma, Inc. Common Stock's current P/E ratio is -8.0x. This places it at the 50th percentile of its historical range.
ArriVent BioPharma, Inc. Common Stock's return on equity (ROE) is -58.9%. The historical average is -60.0%.
Based on historical data, ArriVent BioPharma, Inc. Common Stock is trading at a P/E of -8.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.